Peptoid-peptide hybrids and their use
AssigneesUniversity of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc., Modulation Therapeutics, Inc.
InventorsMARK MCLAUGHLIN, PRIYESH JAIN
Life of this patent
Estimating the term…
Loading patent…
AssigneesUniversity of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc., Modulation Therapeutics, Inc.
InventorsMARK MCLAUGHLIN, PRIYESH JAIN
Estimating the term…
The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid.
A peptoid-body, comprising a cyclic peptoid-peptide hybrid having a beta-hairpin-like conformation, comprising a plurality of alternating peptoid-peptide sequences, each having at least one peptoid residue and an amino acid residue, wherein the peptoid-peptide sequences form at least two antiparallel beta-strands between a plurality of linkers, and wherein at least one linker is a beta-turn promoter.
Dependencies are inferred from the claim text.